Page last updated: 2024-11-12

jaw

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID14973220
CHEMBL ID1435541
CHEBI ID93599
SCHEMBL ID170646
MeSH IDM0011825

Synonyms (46)

Synonym
HMS3267H21
BRD-K91904471-001-01-6
1h-indole-5-carboxamide, 97%
NCGC00162142-01
indole-5-carboxamide
NCGC00162142-02
HMS3229J11
HMS3262M03
bdbm93020
FT-0670336
HMS3244J21
HMS3244I22
HMS3244I21
NCGC00162142-03
LP00701
1670-87-7
AKOS013029770
sd 169
1h-indole-5-carboxamide
5-carboxamidoindole
sd-169
GQMYQEAXTITUAE-UHFFFAOYSA-N
MLS006010711
smr001456333
SCHEMBL170646
tox21_500701
J-504708
NCGC00261386-01
sd169
CHEMBL1435541
1h-indole-5-carboxylic acid amide
DTXSID50566323
mfcd07779486
CHEBI:93599
Q27165292
p38 map kinase inhibitor vii, sd-169 - cas 1670-87-7
Z1151517060
AS-16234
BCP01964
HMS3413H04
SDCCGSBI-0207176.P002
CS-W016161
JAW ,
1~{h}-indole-5-carboxamide
HY-W015445
EN300-1252841

Research Excerpts

Overview

Jaw clonus is an uncommon pathological reflex thought to indicate corticospinal tract dysfunction above the Vth cranial nerve. Jaw forward 50% is a effective jaw forward distance by oral appliance for the treatment of OSAHS.

ExcerptReferenceRelevance
"Jaw shape is a dietary correlate that offers considerable insight on mammalian evolution, but few studies have examined the influence of diet on jaw morphology across mammals."( Feeding ecology has a stronger evolutionary influence on functional morphology than on body mass in mammals.
Grossnickle, DM, 2020
)
1.28
"Jaw clonus is an uncommon pathological reflex thought to indicate corticospinal tract dysfunction above the Vth cranial nerve. "( Jaw clonus frequency does not support hypothesis of peripheral mechanism of self-re-excitation.
Friedman, JH; Mellion, M, 2015
)
3.3
"Jaw forward 50% is a effective jaw forward distance by oral appliance for the treatment of OSAHS and can improve the airway ventilation in OSAHS patients."( [Effect of jaw forward distance on forced inspiratory airflow in patients with obstructive sleep apnea hypopnea syndrome].
Chen, S; He, F; Li, J; Song, XM; Zhang, W; Zhu, QP, 2012
)
2.21
"Jaw osteonecrosis is a severe complication of amino-bisphosphonate therapy. "( Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008
)
2.12
"Jaw wiring is a simple effective procedure which can be carried out in most hospitals, and has a place in an integrated approach to obesity."( Jaw wiring in treatment of obesity.
Burnet, R; Goldney, R; Goss, A; Harding, P; Kimber, C; Phillips, P; Rodgers, S; Thomas, D; Wise, P, 1977
)
2.42

Effects

The jaws have been reverse engineered and represent a human-like mandible and maxilla with artificial teeth. The jaw lift maneuver has been traditionally used to facilitate Trachlight-guided orotracheal intubation.

ExcerptReferenceRelevance
"Jaw displacement has a different effect in jaw openers (digastric and lateral pterygoid) and closers."( Sarcomere length and EMG activity in some jaw muscles of the rabbit.
van der Wielen-Drent, TK; Weijs, WA, 1982
)
1.25
"The jaws have been reverse engineered and represent a human-like mandible and maxilla with artificial teeth."( Prototyping artificial jaws for the robotic dental testing simulator.
Alemzadeh, K; Raabe, D, 2008
)
1.14
"The jaw lift maneuver has been traditionally used to facilitate Trachlight-guided orotracheal intubation. "( Tongue traction is as effective as jaw lift maneuver for Trachlight-guided orotracheal intubation.
George, M; Umesh, G; Venkateswaran, R, 2010
)
1.2
"The jaws have been reverse engineered and represent a human-like mandible and maxilla with artificial teeth."( Prototyping artificial jaws for the Bristol Dento-Munch Robo-Simulator. 'A parallel robot to test dental components and materials'.
Alemzadeh, K; Raabe, D, 2007
)
1.13

Actions

Jaw, lower lip, and upper lip movements were recorded longitudinally in six, 19 month-old children. Articulator movement differences were found between declaratives and interrogatives during the production of vowel and consonant targets.

ExcerptReferenceRelevance
"Jaw muscles enable the motion of this complex and their study is essential for functional and evolutionary analysis."( Functional morphology of the cranio-mandibular complex of the Guira cuckoo (Aves).
Degrange, FJ; Demmel Ferreira, MM; Pestoni, S; Tambussi, CP; Tirao, GA, 2018
)
1.2
"Jaw, lower lip, and upper lip movements were recorded longitudinally in six, 19 month-old children as they began producing the voiceless phoneme /p/. "( Changes in articulator movement variability during phonemic development: a longitudinal study.
Grigos, MI, 2009
)
1.8
"Jaw and lower lip speed, and lower lip range of movement increased with age."( Early speech motor development: Cognitive and linguistic considerations.
Green, JR; Marx, DB; Nip, IS,
)
0.85
"Jaw, lower lip, and upper lip kinematics were examined in 4-, 7-, and 11-year-old children as they produced the declarative and interrogative forms of utterances "Show Bob a bot" and "Show Pop a pot." Articulator movement differences were found between declaratives and interrogatives during the production of vowel and consonant targets."( Articulator movement associated with the development of prosodic control in children.
Grigos, MI; Patel, R, 2007
)
1.06

Toxicity

The aim of this study was to provide an anatomical map for micro-screw placement in a safe location. The most common adverse effects associated with bisphosphonates are renal toxicity, acute-phase reactions, gastrointestinal (GI) toxicity, and osteonecrosis of the jaw (ONJ)

ExcerptReferenceRelevance
" The most common adverse effects associated with bisphosphonates are renal toxicity, acute-phase reactions, gastrointestinal (GI) toxicity, and osteonecrosis of the jaw (ONJ)."( Adverse effects of bisphosphonates: current issues.
Bergner, R; Diel, IJ; Grötz, KA,
)
0.33
"The aim of this study was to provide an anatomical map for micro-screw placement in a safe location between the posterior dental roots of the beagle jaw."( Quantitative research using computed tomographic scanning of beagle jaws for determination of safe zones for micro-screw implantation.
Tang, T; Wang, J; Wei, X; Xu, Z; Yang, Z; Zhao, L; Zhao, Z, 2009
)
0.79
"The data showed that the safe zones were located in the intraradicular spaces of P2, P3, P4, M1, M2 and the interradicular spaces between P4 and M1, M1 and M2 in the mandible; in the maxilla, they were located in the intraradicular spaces of P3, P2, M1 and the interradicular space between P3 and M1."( Quantitative research using computed tomographic scanning of beagle jaws for determination of safe zones for micro-screw implantation.
Tang, T; Wang, J; Wei, X; Xu, Z; Yang, Z; Zhao, L; Zhao, Z, 2009
)
0.59
"The present study provides a map of safe areas for the application of micro-screws in beagles."( Quantitative research using computed tomographic scanning of beagle jaws for determination of safe zones for micro-screw implantation.
Tang, T; Wang, J; Wei, X; Xu, Z; Yang, Z; Zhao, L; Zhao, Z, 2009
)
0.59
" All three 30, 60, and 100 nm Ni NPs are equal to or less toxic than soluble nickel while dendritic clusters were more toxic."( Toxicity and developmental defects of different sizes and shape nickel nanoparticles in zebrafish.
Andreescu, D; Andreescu, S; Goia, DV; Ispas, C; Patel, A; Wallace, KN, 2009
)
0.35
"The aim of this study was to present ultrasound imaging (UI) techniques as promising and safe tools for the follow-up of root-end surgery (RES) in vivo."( Ultrasound Assessment of Bone Healing after Root-end Surgery: Echoes Back to Patient's Safety.
Curvers, F; Lambrechts, P; Meschi, N; Strijbos, O; Van Mierlo, M; Vanhoenacker, A, 2018
)
0.48
" Safety assessments included injection site responses (ISRs), recorded in a subject diary, and adverse events (AEs)."( Safe, Effective Chin and Jaw Restoration With VYC-25L Hyaluronic Acid Injectable Gel.
Abrams, S; Belhaouari, L; Chawla, S; Gaymans, F; Ogilvie, P; Sattler, G; Schumacher, A; Snow, S; Weichman, BM, 2019
)
0.82
"VYC-25L significantly improved glabella-subnasale-pogonion facial angle and was generally safe and well tolerated."( Safe, Effective Chin and Jaw Restoration With VYC-25L Hyaluronic Acid Injectable Gel.
Abrams, S; Belhaouari, L; Chawla, S; Gaymans, F; Ogilvie, P; Sattler, G; Schumacher, A; Snow, S; Weichman, BM, 2019
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
" CGF fibrin combined with Bio-Oss bone powder (Giestlich Pharma, Wolhusen, Switzerland) was used in the test group."( Clinical Application of Concentrated Growth Factor Fibrin Combined With Bone Repair Materials in Jaw Defects.
Fang, D; Hou, J; Long, Z, 2020
)
0.78

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The aim of this case-control study was to identify possible explanatory risk factors for the development of bisphosphonate-related osteonecrosis of the jaws. The study involved 201 patients with multiple myeloma, with or without BRONJ. Analysis of the dose-response curves indicated that tropicamide showed approximately the same potency as atropine.

ExcerptRelevanceReference
" Forty-five patients exhibited some form of neurotoxic reaction that was severe enough in nine patients to require discontinuation of treatment or reduction in dosage of the drug."( Unusual neurotoxicity associated with amiodarone therapy.
Iyer, V; Meckler, RJ; Palakurthy, PR, 1987
)
0.27
"5 to 37 fold) to the right of the dose-response curve for clonidine without significant change of maximum inhibitory effect, in a manner compatible with competitive antagonism (ED50B = 29."( Modulation by central postsynaptic alpha 2-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats.
Barturen, F; García-Sevilla, JA; García-Vallejo, P, 1994
)
0.53
" In contrast, increasing doses of amperozide resulted in decreasing vacuous jaw movements for this portion of the dose-response curve."( The effects of the atypical antipsychotic amperozide on vacuous jaw movements in rats: a novel dose response profile.
Moser, L; Panos, J; Parret, F; Rutell, E; Steinpreis, RE, 1998
)
0.77
"The susceptibility of rainbow trout Oncorhynchus mykiss and brown trout Salmo trutta to Myxobolus cerebralis, the cause of salmonid whirling disease, was assessed following dosed exposures to the infectious stages (triactinomyxons)."( Comparative susceptibility of rainbow trout Oncorhynchus mykiss and brown trout Salmo trutta to Myxobolus cerebralis, the cause of salmonid whirling disease.
Gay, M; Georgiadis, MP; Hedrick, RP; MacConnell, E; Marty, GD; McDowell, TS, 1999
)
0.3
" Dentists can appreciate the immediate onset of anesthesia and reduced dosage levels of anesthetics associated with using IOI."( Intraosseous anesthesia: implications, instrumentation and techniques.
Kleber, CH, 2003
)
0.32
" Analysis of the dose-response curves indicated that tropicamide showed approximately the same potency as atropine for suppression of pilocarpine-induced jaw movements but was more potent than atropine on the suppression of pimozide-induced jaw movements."( The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.
Betz, AJ; Burgos, M; McLaughlin, PJ; Salamone, JD; Weber, SM, 2007
)
0.77
" Gastrointestinal effects occur only with oral agents (clodronate and ibandronate) and may be avoided by adhering to dosing instructions."( Adverse effects of bisphosphonates: current issues.
Bergner, R; Diel, IJ; Grötz, KA,
)
0.13
" Another set of mice were dosed 6 h after exposure and 1 h before assessing airway hyperresponsiveness."( Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation.
Adcock, IM; Chung, KF; Durham, A; Higgins, LS; Issa, R; Kapoun, A; Leung, SY; Medicherla, S; Williams, AS, 2008
)
0.35
" We present evidence that Foxc1 and Fgf8 genetically interact and that Fgf8 dosage is associated with variation in the syngnathic phenotype."( Interaction between Foxc1 and Fgf8 during mammalian jaw patterning and in the pathogenesis of syngnathia.
Inman, KE; Kume, T; Purcell, P; Trainor, PA, 2013
)
0.64
"The aim of this case-control study was to identify possible explanatory risk factors for the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) by estimating the effects of intravenous dosage regimens of bisphosphonates, coexisting diseases, and other drugs on 201 patients with multiple myeloma, with or without BRONJ."( Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma.
Björk, A; Hoffman, T; Jarnbring, F; Kashani, A; Krawiec, K; Ljungman, P; Lund, B, 2015
)
0.82
" In group 2 (n = 6) animals received the identical zoledronate dosage as animals in group 1 and tooth extractions of two premolars (PM 2 and 4) in each jaw (maxilla and mandible) were performed after 12 weeks."( Further development of the MRONJ minipig large animal model.
Ehrenfeld, M; Martin Jurado, O; Nehrbass, D; Otto, S; Pautke, C; Stoddart, MJ; Zeiter, S, 2017
)
0.65
" Rescue of lower-jaw defects in endothelin1 mutants by reducing Nr2f dosage further demonstrates that Nr2f expression must be suppressed for normal lower-jaw development."( Essential Role of Nr2f Nuclear Receptors in Patterning the Vertebrate Upper Jaw.
Barske, L; Behizad, K; Cox, SG; Crump, JG; Del Rio, L; Rataud, P, 2018
)
1.05
" Additionally, dosing with N-acetylcysteine (NAC) effectively mitigated bone loss and normalized expression of ALP, Runx2, and OPN."( The Dual Effects of Reactive Oxygen Species on the Mandibular Alveolar Bone Formation in SOD1 Knockout Mice: Promotion or Inhibition.
Chen, G; Guo, Q; Guo, W; Tian, W; Xu, M; Xu, Y; Yang, Y; Zhang, Y; Zheng, J, 2021
)
0.62
" In the absence of reported MRONJ cases, dental extractions should not be withheld because of previous antiresorptive exposure and antiresorptive medication dosing need not be altered in the pediatric population."( Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Neal, TW; Schlieve, T, 2022
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency32.62940.004110.890331.5287AID493107
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224821
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chymotrypsinogen ABos taurus (cattle)Ki1,326.66670.90004.00008.7000AID1799873
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
digestionChymotrypsinogen ABos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1282488Binding affinity to recombinant N-terminal His-tagged PCAF (715 to 831 residues) (unknown origin) expressed in Escherichia coli Rosetta cells at 1 mM by differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
AID1799873Kinetic Assay from Article 10.1021/bi00877a017: \\INTERACTION OF AROMATIC COMPOUNDS WITH ALPHA-CHYMOTRYPSIN. II. COMBINATION OF THE ISOMERIC INDOLE CARBOXAMIDES AND CARBOXYLATE IONS WITH THE ACTIVE SITE.\\1965Biochemistry, Jan, Volume: 4INTERACTION OF AROMATIC COMPOUNDS WITH ALPHA-CHYMOTRYPSIN. II. COMBINATION OF THE ISOMERIC INDOLE CARBOXAMIDES AND CARBOXYLATE IONS WITH THE ACTIVE SITE.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,940)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902819 (40.62)18.7374
1990's750 (10.81)18.2507
2000's1278 (18.41)29.6817
2010's1599 (23.04)24.3611
2020's494 (7.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 139.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index139.49 (24.57)
Research Supply Index8.95 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index273.36 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (139.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials157 (2.08%)5.53%
Reviews516 (6.83%)6.00%
Case Studies450 (5.96%)4.05%
Observational15 (0.20%)0.25%
Other6,416 (84.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]